Mumbai: From gummies for healthier hair and effervescent tablets for weight loss to pills claiming to balance hormones and the recent protein frenzy, India’s nutraceutical market is growing at an unprecedented pace.
The sector was valued at USD 38.77 billion in 2025 and is projected to reach USD 84.99 billion by 2033, growing at a CAGR of 10.3 per cent between 2026 and 2033, according to market research firm Grand View Research.
But this growth has been accompanied by a rise in products promising to prevent, manage or even reverse health conditions, raising concerns over misleading claims, questionable product quality and the risks to consumers.
With the market on track to more than double in size in less than a decade, is India’s regulatory framework prepared to keep up?
ETHealthworld takes a closer look at what’s wrong with the market at present, gaps within the existing regulatory framework and what needs to change as nutraceuticals take on a more mainstream role in the lives of consumers.
Marketability vs Efficacy
At the centre of the problem is a growing disconnect between what nutraceutical brands promise and what their products can actually deliver. As competition intensifies, brands are increasingly using specific health and efficacy claims to differentiate their products, often without sufficient scientific evidence to back them.
This is highlighted in the findings of a recent report by the Advertising Standards Council of India (ASCI).
In its report, ‘A Pill for Thought: Review of Health and Wellness Claims in Nutraceutical Advertising’ based on the suo-motu investigation of nutraceutical ads between July and September 2026, ASCI found all 60 ads reviewed to be in violation of its code.
The main concern was exaggerated outcomes and misleading visuals, which could create unrealistic expectations and blur the line between general wellness support and medical treatment.
The key violations related to claims around weight management, anti-ageing, skin lightening, UV protection and respiratory health, with ads claiming to address conditions such as asthma, chronic obstructive pulmonary disease (COPD), blood pressure, cholesterol and PCOS.
Examples of such claims include “Lose 6 kgs in 60 days”, “Your thigh fat will be gone in 12 weeks” and “300 per cent stronger skin defence against UV damage”.
With most of these products being sold over the counter, this could have a serious impact on consumer safety, said Dr Rajiv Kovil, Mumbai-based Diabetologist. He pointed to the recent surge in supplements marketed as fat burners or diabetes reversal aids, some even pitched as alternatives to GLP-1 drugs.
“There is no convincing clinical evidence that any nutraceutical can independently produce substantial, sustained weight loss or reverse diabetes. Claims such as “fat burner”, “natural Ozempic”, “GLP-1 booster” or “diabetes reversal supplement” are often scientifically misleading.”
“What worries me most is the false sense of security these products create. Patients may postpone evidence-based treatment while experimenting with supplements that have little proven benefit. Some products may also contain undisclosed pharmaceutical ingredients or interact with diabetes medications, potentially increasing the risk of hypoglycaemia or other adverse effects,” he added.
The risks are not limited to people managing a medical condition. Dr. Eileen Canday, Head of Department, Nutrition & Dietetics noted that supplements are increasingly being used to replace a balanced diet.
“In consults, I increasingly see supplements added before diets are even assessed. Protein powders replace meals, multivitamins become ‘insurance’ for poor eating, and fat burners or detox products promise what no product can deliver. I’ve seen people stack several products with overlapping ingredients, exceed safe limits for vitamins A and D or zinc, and use caffeine-heavy fat burners that cause palpitations and poor sleep. Some skip balanced meals altogether.”
Are existing regulations enough?
Nutraceuticals are regulated as food products and their manufacture, composition and labelling are governed by the Food Safety and Standards (Health Supplements, Nutraceuticals, Food for Special Dietary Use, Food for Special Medical Purpose, Functional Food and Novel Food) Regulations, 2022.
The regulations prescribe permitted ingredients and their limits, set labelling and disclosure requirements, and prohibit products from making medicinal claims or suggesting that they can prevent, treat or cure diseases.
But the growing instances of misleading claims and non-compliance have raised questions about how effectively these provisions are being monitored and enforced.
In January 2024, the Union health ministry set up a high-level inter-ministerial panel saying that existing norms on nutraceuticals were not adequate, pointing to the blurred line between drugs and supplements.
The panel, headed by then Apurva Chandra, Union Health Secretary submitted its report to the government in November 2024, recommending regulating health supplements such as vitamins, minerals, prebiotic and probiotic formulations in dosage strength as pharmaceutical products in order to ensure better due diligence before their approval, and to control production quality and price.
It also suggested that while the FSSAI may continue to regulate nutritional and health claims made by nutraceuticals, their claim to cure or mitigate any specific disease, disorder or condition including disease risk reduction should be regulated by the Central Drugs Standard Control Organisation (CDSCO).
With the recommendations yet to translate into change, FSSAI officials have said that ensuring product quality and safety is primarily the responsibility of manufacturers.
In July this year, Pritee Chaudhary, Regional Director (Western Region), FSSAI, told ETHealthworld that while the regulator has established regulations and an advertisement monitoring mechanism to scrutinise product safety and claims, food businesses must take greater responsibility for compliance.
“The major responsibility to ensure products are safe and of high quality lies with food businesses themselves. As India moves towards greater self-reliance, self-assessment and self-compliance, the responsibility increasingly shifts to manufacturers rather than regulators,” she said.
“The government’s role is not to enforce every aspect through regulation but to adopt a model of minimal enforcement while creating greater awareness and promoting education,” she added.
The position raises a larger question for a rapidly expanding market: can a framework that places much of the responsibility on manufacturers ensure adequate consumer protection, particularly when misleading claims and compliance failures continue to surface?
ETHealthworld reached out to Chaudhary for further comment. The request remained unanswered at the time of publication.
Stronger testing and surveillance
Experts say closing the gap will need stronger testing, tighter surveillance, clearer accountability and regulatory reform that keeps pace with the market.
Dr Mona Duggal, Director, ICMR- National Institute for Research in Digital Health said the starting point is evidence and clear labelling.
“Regulation is still wanting in this area. We need the right evidence in place, and clarity on what food labels should say, so that people are aware of what they are taking. A better understanding of how nutraceuticals work, for the general layperson, is going to be very important.”
Drawing on lessons from India’s food fortification programmes, she says monitoring must continue after products reach the market.
“Any time you start a program, you have to have a very strong post-market surveillance. Once you introduce something, you have to ensure there is a continuous loop. Vitamin A, for instance, was one of the first fortification success stories, but now we are seeing side effects if the program is not well monitored.”
As more brands compete for a share of India’s nutraceutical boom, the question is whether the regulatory framework can evolve quickly enough to ensure that the promise of better health does not come at the cost of consumer safety.
